> The issue is systemic. Yeah, this drug only has a few people, another drug only has a few other people, etc. But looking at it from a per drug perspective is

> The issue is systemic. Yeah, this drug only has a few people, another drug only has a few other people, etc. But looking at it from a per drug perspective is not seeing the forest through the trees. I don't understand, because it sounds like you're trying to argue with what I'm saying, but we're literally making the same point. Shkreli makes for an easy target because he's the absolute caricature of a villain. But at the same time, focusing on this drug misses the point. Even if Shkreli cut the price of the drug to $0, there would be no measurable effect on patients. And while not everyone is as overtly malevolent as Shkreli is, the incentives that cause this sort of behavior aren't caused by the pharmaceutical companies (nor can they really be fixed by the pharmaceutical companies - at least not systemically - because they're just responding to the incentives that have already been created).